brivanib alaninate Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC, the most common type of liver cancer. Brivanib is no longer in active development.   Wikipedia

Chemistry

  • SMILES: C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N
  • InChIKey: LTEJRLHKIYCEOX-OCCSQVGLSA-N
  • Mol. Mass: 441.46
  • ALogP: 3.42
  • ChEMBL Molecules:
    brivanib alaninate  
    brivanib  
More Chemistry

Pharmacology

Alternative names

bms540215 | bms 540215 | bms-540215 | bms582664 | bms 582664 | bms-582664 | brivanib | brivanib alaninate

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Colorectal Neoplasms (Phase 3)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 1)

Intestinal Neoplasms (Phase 1)

Liver Cirrhosis, Biliary (Phase 1)

Liver Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Stents (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue